Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Hartford, Connecticut 06105


Purpose:

The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.


Criteria:

Inclusion Criteria: - Documented colorectal cancer which is EGFR-positive and is metastatic. - Prior irinotecan, alone or in combination, as first-line treatment of metastatic disease. Exclusion Criteria: - A serious uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive protocol therapy. - Known dihydropyrimidine dehydrogenase (DPD) deficiency. - Known metastases in the central nervous system. - Symptomatic sensory or peripheral neuropathy. - More than one prior chemotherapy regimen for the treatment of metastatic colorectal cancer. - Prior oxaliplatin therapy. - Prior cetuximab or other therapy which targets the EGF pathway. - Prior chimerized or murine monoclonal antibody therapy.


NCT ID:

NCT00061815


Primary Contact:

Study Chair
E-mail: ClinicalTrials@ ImClone.com
ImClone LLC


Backup Contact:

N/A


Location Contact:

Hartford, Connecticut 06105
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.